Supra Pacific Financial Services Limited has received listing and trading approval from BSE for 1,58,52,525 equity shares issued on rights basis. The company announced that BSE granted listing approval on April 1, 2026, with trading approval effective from April 2, 2026.

BSE Approval Details

The company received comprehensive approvals from BSE for its rights issue shares, marking the completion of the regulatory process initiated following the successful rights issue allotment.

Rights Issue Share Specifications

The approved shares carry specific distinctive numbers and are issued at a premium, ranking pari-passu with existing equity shares of the company.

Previous Rights Issue Performance

The rights issue, which opened for subscription on March 20, 2026 and closed on March 27, 2026, achieved a subscription rate of 72.92%. The company successfully processed 466 valid applications out of 536 total applications received.

Capital Structure Impact

Following the successful allotment and BSE approval, the company's paid-up equity share capital has increased substantially, representing a significant expansion in the capital base.

The BSE approval completes the regulatory process for the rights issue, with the newly issued shares now available for trading on the exchange. The company has maintained full compliance with all regulatory requirements throughout the rights issue process.

Supra Pacific Financial Services Limited has successfully concluded its board meeting held on April 2, 2026, approving the issuance of ₹20 crore Non-convertible Debentures and other strategic corporate decisions. The meeting, which commenced at 10:30 a.m. and concluded at 3:15 p.m., addressed critical fundraising and operational matters as outlined in the company's regulatory compliance framework under Regulation 30 of SEBI Listing Regulations.

Board Meeting Outcomes

The board meeting resulted in several key approvals and decisions that will shape the company's immediate operational and financial strategy. The directors successfully addressed all agenda items while maintaining strict adherence to regulatory requirements and SEBI Circular guidelines.

NCD Issuance Details

The board approved the issuance of 2,00,000 Non-convertible Debentures aggregating to ₹20 crore on a private placement basis. The securities will remain unlisted and unrated, targeting investors with minimum subscription requirements of ₹1 crore or above per investor under the secured category.

Interest Payment Structure

The debentures offer flexible interest payment options to cater to different investor preferences. The monthly option provides 11.60% annual interest with monthly payouts throughout the 2-year tenure, while the yearly option offers 11.75% with annual interest payments. Principal repayment will occur at maturity after 2 years from the allotment date.

Debenture Committee Formation

The board constituted a dedicated Debenture Committee to oversee the allotment process and ensure efficient execution of the NCD issuance. The committee comprises three members with specific roles and comprehensive authority over the subscription and allotment process.

The committee holds authority to approve debenture allotments based on subscription processes, finalize investor selections considering oversubscription scenarios, manage notification processes for subscribers, and handle technical adjustments or discrepancies during the allotment phase including corrections for errors or changes in investor eligibility.

Registered Office Relocation

The board discussed the proposed relocation of the company's registered office from Dreamax Height, Shop No. 1, First floor, Upadhyay Compound, Jija Mata Road, Near PumpHouse, Andheri East, Chakala Midc, Mumbai to Kanakia Wallstreet, A Wing, unit no 1107, Andheri Kurla Road, Andheri (East), Mumbai 400093. The relocation aims to enhance operational convenience and support business expansion initiatives while maintaining the Mumbai jurisdiction.

Regulatory Compliance

The meeting outcome has been filed under reference SPFSL/BSE/SEC/2026-27/02 in compliance with Regulation 30 of SEBI Listing Regulations and Schedule III requirements, along with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. Company Secretary Leena Yezhuvath digitally signed the regulatory filing on April 2, 2026, ensuring full compliance with prescribed disclosure norms for the BSE-listed entity trading under scrip code 540168.